Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 11/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | IDH1 | O75874 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | VNN1 | O95497 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19091172 | 0.87 | MEP1B (0.53) | MEP1BKDM1AMAOAMAOBF10 | |
| SCHEMBL19954228 | 0.86 | MEP1B (0.63) | MEP1BALDH1A1KMT2AL3MBTL1FOLH1 | |
| SCHEMBL14558488 | 0.84 | MEP1B (0.54) | MEP1BKDM1AMAOAMAOBF10 | |
| SCHEMBL19954255 | 0.84 | LOXL2 (0.59) | MEP1BALDH1A1KMT2AFOLH1 | |
| SCHEMBL19954186 | 0.81 | MEP1B (0.48) | MEP1BALDH1A1KDM1AMAOAMAOB | |
| SCHEMBL20987986 | 0.81 | EPHX2 (0.49) | ALDH1A1KMT2AL3MBTL1KDM1AMAOA | |
| SCHEMBL2570385 | 0.79 | NOS1 (0.54) | MEP1BKDM1AMAOAMAOBF10 | |
| SCHEMBL10295479 | 0.78 | F2 (0.44) | MEP1BF10IDH1PARP1FOLH1 | |
| SCHEMBL15061150 | 0.78 | FNTA (0.52) | MEP1BKMT2AKDM1AMAOAMAOB | |
| SCHEMBL5005534 | 0.78 | MEP1B (0.52) | MEP1BKMT2AKDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696707-B2 | Polyene macrolide derivative | SHIONOGI & CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| US-20190135847-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2019-05-09 | — | — | US | disclosed |
| US-9914740-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135847-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | MEP1B 286/4885ALDH1A1 4446/4885KMT2A 2653/4885 |
| US-10696707-B2 | Polyene macrolide derivative | ERG28, RPL23, RPL10 | MEP1B 286/4885ALDH1A1 4446/4885KMT2A 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.